コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 polyangiitis, but are absent in microscopic polyangiitis.
2 reatment of eosinophilic granulomatosis with polyangiitis.
3 orbital inflammation, or granulomatosis with polyangiitis.
4 f the PR3 autoantigen in granulomatosis with polyangiitis.
5 toplasmic antibodies) in granulomatosis with polyangiitis.
6 ith diagnosed Wegener disease or microscopic polyangiitis.
7 ce injury in MPO-ANCA-associated microscopic polyangiitis.
8 as Wegener's granulomatosis) and microscopic polyangiitis.
9 ther Wegener's granulomatosis or microscopic polyangiitis.
10 condition a separate entity from microscopic polyangiitis.
11 is as Wegener granulomatosis and microscopic polyangiitis.
12 egener's granulomatosis [WG], 12 microscopic polyangiitis, 16 Churg-Strauss syndrome [CSS]), and anti
13 rolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 wi
16 id Arthritis (aHR=0.64), Granulomatosis with Polyangiitis (aHR=0.21), or Systemic Lupus Erythematosus
17 matosis with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA (EGPA), are defined ac
18 c autoantibody (ANCA)-associated microscopic polyangiitis and glomerulonephritis (excluding Wegener's
21 tic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis that are assoc
22 vasculitis and also that granulomatosis with polyangiitis and microscopic polyangiitis were genetical
23 ts of two main diseases, granulomatosis with polyangiitis and microscopic polyangiitis, and remains a
24 resistance in 107 patients with microscopic polyangiitis and necrotizing and crescentic glomerulonep
26 d AAV (Wegener granulomatosis or microscopic polyangiitis) and were aged 18 to 75 years at diagnosis.
27 tosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated v
29 's disease, eosinophilic granulomatosis with polyangiitis, and immunoglobulin A (IgA) vasculitis by a
31 ulomatosis with polyangiitis and microscopic polyangiitis, and remains among the most devastating and
33 ulomatosis with polyangiitis and microscopic polyangiitis are characterised by a necrotising vasculit
34 with Wegener granulomatosis and microscopic polyangiitis are derived by extrapolating from data abou
35 athological hallmarks of granulomatosis with polyangiitis, but are absent in microscopic polyangiitis
37 esponses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); and matrix metall
40 (MPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), also collectively re
41 e including eosinophilic granulomatosis with polyangiitis (EGPA) accounted for 85 subjects (20%) of w
42 tients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission.
52 rome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a mul
53 s (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), that share features of pauci-immune
58 (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss), are a group
60 phils from patients with granulomatosis with polyangiitis expressing high membrane PR3 levels showed
61 ing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis
63 a 15-year-old girl with granulomatosis with polyangiitis, formerly known as Wegener's granulomatosis
65 tion with categories for granulomatosis with polyangiitis (GPA) (Wegener's), microscopic polyangiitis
66 mal gland involvement in granulomatosis with polyangiitis (GPA) commonly accompanies orbital disease,
67 Ocular manifestations of granulomatosis with polyangiitis (GPA) have been reported in a limited numbe
73 tions in ANCA-associated granulomatosis with polyangiitis (GPA) may be present, however, severe, life
75 opic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with
76 t interrelated diseases: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and e
77 sculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and e
78 mirroring patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and
79 ee AAV subgroups, namely granulomatosis with polyangiitis (GPA), microscopic polyangiitis and eosinop
81 c polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), share similarities but differ in cli
86 omatous lesions found in granulomatosis with polyangiitis (GPA, formerly Wegener's) or the developmen
87 associated vasculitides, granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic poly
90 We report the development of eosinophilic polyangiitis granulomatosis (EGPA) in a young girl being
92 al features of kidney disease in microscopic polyangiitis have been associated with clinical presenta
93 condition, most commonly granulomatosis with polyangiitis; however, bilaterality was not associated w
94 monstrates greater similarity to microscopic polyangiitis in relapse rate than previously reported.
99 nagement of renal involvement in microscopic polyangiitis is discussed, with emphasis on prognosis an
100 PR3), the autoantigen in granulomatosis with polyangiitis, is expressed at the plasma membrane of res
101 sis, Churg-Strauss syndrome, and microscopic polyangiitis, is impeded by the small number of pediatri
102 ipants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more
103 cludes Wegener's granulomatosis, microscopic polyangiitis (microscopic polyarteritis), the Churg-Stra
104 c lymphocytic leukaemia, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vu
105 y diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited
106 matosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with
107 matosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with
110 egener's granulomatosis (WG) and microscopic polyangiitis (MPA) have been reported to be pathological
112 matosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with
113 iitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with
114 h polyangiitis (Wegener's; GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with
115 polyangiitis (GPA) (Wegener's), microscopic polyangiitis (MPA), and kidney-limited disease; 2) the E
116 rse patterns of injury including microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GP
117 hy include polyarteritis nodosa, microscopic polyangiitis (MPA), rheumatoid vasculitis, Churg-Strauss
119 ve patients (64 with WG, 14 with microscopic polyangiitis [MPA], and 526 others) and 45 healthy volun
121 creased in patients with granulomatosis with polyangiitis, MVs generated from neutrophils expressing
122 ived a KTX for ESRD secondary to microscopic polyangiitis (n=43) or Wegener's granulomatosis (n=42).
123 oncluded that most patients with microscopic polyangiitis or necrotizing and crescentic glomeruloneph
124 matosis with polyangiitis versus microscopic polyangiitis), or new diagnosis (versus relapsing diseas
125 ranulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculiti
126 rythematosus (P = 2.7 x 10(-8)), microscopic polyangiitis (P = 2.9 x 10(-4)) and Wegener's granulomat
127 il cytoplasmic antibody-positive microscopic polyangiitis, resulting in pulmonary hemorrhage and acut
129 as rheumatoid arthritis, granulomatosis with polyangiitis, Sjogren's syndrome, sarcoidosis, and infec
130 ulomatosis with polyangiitis and microscopic polyangiitis that are associated with ANCA specificity,
131 ntrolling for age, ANCA pattern, microscopic polyangiitis versus glomerulonephritis alone, and pulmon
132 NCA type, AAV diagnosis (granulomatosis with polyangiitis versus microscopic polyangiitis), or new di
138 b (RTX) in patients with granulomatosis with polyangiitis (Wegener's; GPA), microscopic polyangiitis
141 itivity and eosinophilic granulomatosis with polyangiitis, which accounted for 34.1% and 12.8% of cas
142 refractory eosinophilic granulomatosis with polyangiitis who had received treatment for at least 4 w